Adjuvant chemotherapy in luminal breast cancers

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Luminal breast cancers, characterized by estrogen receptor (ER) expression, are the most common type.
• These tumors exhibit significant heterogeneity in molecular profiles and response to therapies.
• While endocrine therapy is standard for ER-positive/progesterone receptor-positive (PR+) breast cancer, chemotherapy indications are less defined.

Purpose of the Study:

• To discuss the utility of current biomarkers in guiding chemotherapy decisions for ER-positive, HER2-negative breast cancers.
• To identify patient subgroups who benefit from endocrine therapy alone versus those who require adjuvant chemotherapy.
• To improve personalized treatment strategies for ER-positive breast cancer patients.

Main Methods:

• Review of current literature on biomarkers for ER-positive, HER2-negative breast cancer.
• Analysis of clinical trial data and treatment guidelines.
• Discussion of prognostic and predictive biomarker utility.

Main Results:

• ER-positive tumors generally benefit less from chemotherapy than ER-negative tumors, but a chemosensitive subset exists.
• Current chemotherapy decisions rely heavily on clinical estimation of prognosis and endocrine sensitivity.
• Biomarker utility in distinguishing chemosensitive ER-positive patients is variable and requires further investigation.

Conclusions:

• Accurate identification of patients who will benefit from chemotherapy in the ER-positive, HER2-negative setting is critical.
• Further research into predictive biomarkers is needed to optimize adjuvant treatment strategies.
• Personalized medicine approaches can spare patients unnecessary toxicity and improve outcomes.